Abbvie Inc
NYSE: ABBV
$193.62
+$0.68 (+0.4%)
Closing Price on September 19, 2024
ABBV Articles
Here are a few big biopharma names on which Wall Street is growing more bearish.
Published:
Monday's top analyst upgrades and downgrades included AbbVie, Alcoa, Alibaba, Best Buy, Beyond Meat, Block, Coinbase Global, Foot Locker, GoPro, Home Depot, Lithium Americas, Nvidia, TotalEnergies,...
Published:
Thursday afternoon's top analyst upgrades and downgrades included AbbVie, First Solar, The Gap, Qualcomm, Spotify and more.
Published:
We have previewed here three big health care companies, along with the country's largest oil refiner and marketer.
Published:
Friday's top analyst upgrades and downgrades included AbbVie, Chipotle Mexican Grill, Costco Wholesale, Crocs, Dominion Energy, Enphase Energy, Ford, Hertz, KeyCorp, Kite Realty, Riot Blockchain,...
Published:
Wednesday afternoon's top analyst upgrades and downgrades included AbbVie, Biogen, DoorDash, Kratos Defense, PayPal and more.
Published:
These five Dividend Aristocrats are in sectors that have underperformed in 2021 or are solid plays as investors continue to deal with both rising inflation and the potential for rising interest rates...
Published:
Thursday afternoon's top analyst upgrades and downgrades included AbbVie, Allstate, Amgen, Occidental Petroleum, Pfizer, SunPower, Twilio and Yum! Brands.
Published:
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Published:
Now is the time to reduce risk and more to safer ideas. Top-quality health care stocks may be the way to go for the rest of 2021 and in 2022, and these five Dividend Aristocrats make good sense now...
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Altice USA, Amazon.com, Comcast, General Electric, Kimco Realty, Micron Technology, Nvidia, Salesforce.com, StoneCo, Western Digital,...
Published:
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Published:
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
Published:
These five top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Published:
Hedge fund managers are getting more defensive, and it is probably high-time individual investors do as well. These five stocks come with reliable dividends, are not overextended and are rated Buy at...
Published: